Search Results - "programmed cell death‐1"

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.

Hasegawa, Kosei, Takahashi, Shunji, Ushijima, Kimio, Okadome, Masao, Yonemori, Kan, Yokota, Harushige, Vergote, Ignace, Monk, Bradley, Tewari, Krishnansu, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Paccaly, Anne, Takehara, Kazuhiro, Usami, Tomoka, Aoki, Yoichi, Suzuki, Nao, Kobayashi, Yoichi, Yoshida, Yoshio, Watari, Hidemichi, Seebach, Frank, Lowy, Israel, Mathias, Melissa, Fury, Matthew, Oaknin, Ana

application/pdf

Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study

Boucheron T, Chiche L, Penaranda G, Souquet M, Pegliasco H, Deturmeny J, Brunel V, Barrière N, Arbault-Bitton C, Coquet E, Diaz L, Escoda T

electronic resource

View item; View item

Transcutaneous Imiquimod Combined With Anti‐Programmed Cell Death‐1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell Carcinoma

Takashi Karashima, Toshihiro Komatsu, Shinkuro Yamamoto, Kaya Atagi, Hatsune Hashida, Hideo Fukuhara, Kenji Tamura, Shingo Ashida, Taro Shuin, Keiko Udaka, Takahiro Shimizu, Motoaki Saito, Nobutaka Shimizu, Keiji Inoue

electronic resource

View item

The Significant Impact of Programmed Cell Death-1 Gene Polymorphism on HBV Infection and Viral Load

Hiba Hadi Rashid, Hiba M. Al-Darraji, Müge FIRAT, Bassam Mohammed Mishkhal

electronic resource

View item; View item; View item

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion

Zhang, Yufeng^{Aff1, Aff2}, Zhang, Haiyan^{Aff1, Aff2}, Xu, Haoqian^{Aff1, Aff2}, Wang, Ying^{Aff1, Aff2}, Feng, Long^{Aff1, Aff2, IDs12957024033964_cor5}, Yi, Fengming^{Aff1, Aff2, IDs12957024033964_cor6}

Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease

Cieplińska, Katarzyna ^{a, ⁎}, Niedziela, Emilia ^{b, c}, Rdzanek, Agata Kopacz ^a, Słuszniak, Anna ^a, Chrapek, Magdalena ^d, Pałyga, Iwona ^{b, c}, Kowalska, Aldona ^{b, c}

Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study

Chunyan Lan, Huaiwu Lu, Lin Zhou, Kunlun Liao, Junxiu Liu, Zhiwen Xie, Haixi Liang, Guorong Zou, Ting Yang, Qin Xu, Xin Huang

electronic resource

View item

PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation – therapeutic implications for autoimmunity

Feng, Yiqing ^a, Deyanat-Yazdi, Gordafaried ^b, Newburn, Kristin ^a, Potter, Scott ^b, Wortinger, Mark ^c, Ramirez, Miriam ^b, Truhlar, Stephanie M.E. ^d, Yachi, Pia P. ^{b, ⁎}

Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab

Yuki Sasaki, Kazuyuki Matsumoto, Akinobu Takaki, Takuya Adachi, Masahiro Takahara, Keita Ozato, Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Takashi Oda, Koichiro Tsutsumi, Kazuhiro Nouso, Kazuya Kariyama, Hiroaki Hagihara, Akio Moriya, Motoyuki Otsuka

electronic resource

View item; View item

Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature

Kang, Yan, Zhen, Hongchao, Ma, Nina, Zhao, Hong, Cao, Bangwei^{Aff1, IDs00432023053283_cor5}

Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer

Takamori, Shinkichi^{Aff1, Aff2}, Shimokawa, Mototsugu, Komiya, Takefumi^{Aff4, IDs00432023051672_cor3}

Extracellular vesicle–based drug delivery in cancer immunotherapy

Najafi, Sajad^{Aff1, Aff2}, Majidpoor, Jamal, Mortezaee, Keywan^{Aff4, IDs13346023013703_cor1}

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J. Monk, Krishnansu S. Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Anne Paccaly, Kazuhiro Takehara, Tomoka Usami, Yoichi Aoki, Nao Suzuki, Yoichi Kobayashi, Yoshio Yoshida, Hidemichi Watari, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin

electronic resource

View item

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma

Seiwert, Tanguy Y., Wildsmith, Sophie^{Aff2, IDs00262024036433_cor2}, Fayette, Jérôme, Harrington, Kevin, Gillison, Maura, Ahn, Myung-Ju, Takahashi, Shunji, Weiss, Jared, Machiels, Jean-Pascal, Baxi, Shrujal, Baker, Valerie, Evans, Brent, Morsli, Nassim, Jill Walker, Real, Katia, L’Hernault, Anne, Psyrri, Amanda

Cutaneous T-cell lymphoma developing during nivolumab treatment for metastatic melanoma

Hida, Yasutoshi, Kageji, Riho, Bekku, Hirofumi, Watanabe, Shunsuke, Seike, Takuya, Yamashita, Michiko

application/pdf

Management of multisystemic irAEs associated with atezolizumab/tiragolumab combination therapy in a patient with lung adenocarcinoma: case report and review

Zhang, Shilong^{Aff1, Aff2}, Zhang, Ningping, Lin, Jinyi, Zhao, Lin, Jin, Hang, Gao, Di, Ji, Zongfei, Liu, Qing^{Aff1, Aff2}, Ai, Luoyan^{Aff1, Aff2}, Yu, Yiyi^{Aff1, Aff2, IDs44272025000342_cor1}

Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma

Jialiang Wang, Xiaoyu Zhang, Xinyi Ma, Dongmei Chen, Meina Cai, Lexin Xiao, Jing Li, Zexuan Huang, Yuehua Huang, Yifan Lian

electronic resource

View item

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis

Tzu-Rong Peng, Li-Jou Yang, Ta-Wei Wu

electronic resource

View item; View item; View item

Characteristic differences in the abundance of tumor-infiltrating lymphocytes and intratumoral developing T cells in thymoma, with special reference to PD-1 expression

Furuya, Tatsuo^{Aff1, Aff2}, Ishihara, Shunta, Ogi, Hiroshi^{Aff3, Aff4}, Masuda, Kyoko, Shibata, Saya, Nakazono, Chiaki, Okada, Satoru, Shimomura, Masanori, Tando, So, Yaoi, Takeshi, Maeda, Yoshinobu, Yamagishi, Masaaki, Kawamoto, Hiroshi, Itoh, Kyoko, Inoue, Masayoshi^{Aff1, IDs00262023034315_cor15}

Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer

Zhao, Yan^{Aff1, Aff2}, Liu, Yueping, Jia, Yunlong, Wang, Xiaoxiao, He, Jiankun, Zhen, Shuman, Wang, Jiali, Liu, Lihua^{Aff1, Aff4, Aff5, IDs00432022042504_cor8}